Kura Oncology, Inc. (NASDAQ:KURA) Receives $29.86 Consensus Target Price from Analysts

Kura Oncology, Inc. (NASDAQ:KURA) has been given an average recommendation of “Buy” by the ten analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $29.86.

A number of analysts have recently weighed in on the company. Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. TD Cowen restated a “buy” rating on shares of Kura Oncology in a research note on Thursday, November 21st. UBS Group started coverage on shares of Kura Oncology in a report on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective on the stock. Bank of America lowered their target price on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, November 22nd. Finally, Stifel Nicolaus lowered shares of Kura Oncology from a “buy” rating to a “hold” rating and cut their price target for the company from $26.00 to $19.00 in a research note on Monday, October 14th.

Kura Oncology Trading Up 0.6 %

NASDAQ:KURA opened at $8.73 on Monday. The stock has a market capitalization of $678.88 million, a price-to-earnings ratio of -3.70 and a beta of 0.75. Kura Oncology has a 52 week low of $8.42 and a 52 week high of $24.17. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm has a 50 day moving average of $12.48 and a 200 day moving average of $17.28.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in KURA. Bank of New York Mellon Corp grew its position in Kura Oncology by 4.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 255,897 shares of the company’s stock worth $5,269,000 after purchasing an additional 11,212 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Kura Oncology by 34.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,060 shares of the company’s stock worth $372,000 after acquiring an additional 4,654 shares during the period. Candriam S.C.A. raised its position in Kura Oncology by 39.2% during the second quarter. Candriam S.C.A. now owns 906,482 shares of the company’s stock valued at $18,664,000 after acquiring an additional 255,065 shares in the last quarter. Sofinnova Investments Inc. lifted its holdings in Kura Oncology by 64.4% in the second quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock valued at $16,992,000 after acquiring an additional 323,303 shares during the period. Finally, Hsbc Holdings PLC boosted its position in Kura Oncology by 13.4% in the 2nd quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock worth $374,000 after purchasing an additional 2,167 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.